Multiple sclerosis treated with alemtuzumab : a newly documented complication


  • Relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab has been associated with invasive pulmonary aspergillosis (IPA) for the first time.

Why this matters ?

  • Although risk of severe infection with alemtuzumab is reportedly low, clinicians should be vigilant for IPA and settle for probable diagnosis as a means of avoiding delayed treatment.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.